{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:01Z","timestamp":1792081501796,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.esmoop.2021.100315","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T19:24:06Z","timestamp":1638473046000},"page":"100315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-7987","authenticated-orcid":false,"given":"N.E.","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9539-8167","authenticated-orcid":false,"given":"A.I.","family":"Fahmy Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-1166","authenticated-orcid":false,"given":"M.","family":"Eshra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9774-0483","authenticated-orcid":false,"given":"T.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abou-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2021.100315_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7010","key":"10.1016\/j.esmoop.2021.100315_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/bmj.311.7010.889","article-title":"Chemotherapy for non-small cell lung cancer","volume":"311","author":"Carbone","year":"1995","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100315_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11912-017-0587-4","article-title":"Changing the therapeutic landscape in non-small cell lung cancers: the evolution of comprehensive molecular profiling improves access to therapy","volume":"19","author":"Sabari","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2021.100315_bib4","first-page":"524","article-title":"How I treat ALK-positive non-small cell lung cancer","volume":"4","author":"McCusker","year":"2019","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100315_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/esmoopen-2019-000548","article-title":"From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer","volume":"4","author":"Pirker","year":"2019","journal-title":"ESMO Open"},{"issue":"31","key":"10.1016\/j.esmoop.2021.100315_bib6","doi-asserted-by":"crossref","first-page":"22137","DOI":"10.18632\/oncotarget.25154","article-title":"Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer","volume":"9","author":"Costa","year":"2018","journal-title":"Oncotarget"},{"issue":"10089","key":"10.1016\/j.esmoop.2021.100315_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.esmoop.2021.100315_bib8","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100315_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2021.100315_bib10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100315_bib11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100315_bib12","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.2147\/CMAR.S190098","article-title":"The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"23","key":"10.1016\/j.esmoop.2021.100315_bib13","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.2169\/internalmedicine.8214-16","article-title":"Crizotinib-induced rectal perforation with abscess","volume":"56","author":"Yanagisawa","year":"2017","journal-title":"Intern Med"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100315_bib14","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2217\/fon-2018-0608","article-title":"Ocular and orbital side effects of ALK inhibitors: a review article","volume":"15","author":"Chelala","year":"2019","journal-title":"Futur Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100315_bib15","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1200\/JCO.2013.49.1985","article-title":"Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK Translocation","volume":"33","author":"Chun","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12885-019-6486-3","article-title":"Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report","volume":"20","author":"Guisier","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100315_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10637-018-0605-x","article-title":"Crizotinib-induced simultaneous multiple cardiac toxicities","volume":"36","author":"Oyakawa","year":"2018","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100315_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/15563650.2019.1678755","article-title":"Implantable cardioverter defibrillator for alectinib induced ventricular fibrillation","volume":"58","author":"Mandal","year":"2020","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.esmoop.2021.100315_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2018.03.023","article-title":"Lorlatinib-induced pulmonary arterial hypertension","volume":"120","author":"Chabrol","year":"2018","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100315_bib20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1078155220904141","article-title":"Life-threatening hypertriglyceridemia-induced pancreatitis related to alectinib successfully treated by plasmapheresis: a review of the literature on metabolic toxicities associated with anaplastic lymphoma kinase inhibitors","volume":"26","author":"Rao","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100315_bib21","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jtho.2017.04.006","article-title":"Chronic cholestasis with dilation of intrahepatic bile duct related to administration of ceritinib","volume":"12","author":"Hirano","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000445288","article-title":"Alectinib-induced alopecia in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"9","author":"Koizumi","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.esmoop.2021.100315_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1078155220961549","article-title":"Lorlatinib induced proteinuria: a case report","volume":"27","author":"Lee","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.esmoop.2021.100315_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2018.06.024","article-title":"New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent","volume":"392","author":"Desai","year":"2018","journal-title":"J\u00a0Neurol Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100315_bib25","first-page":"457","article-title":"Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient","volume":"8","author":"Yang","year":"2018","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100315_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s10637-018-0652-3","article-title":"Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib","volume":"37","author":"Facchinetti","year":"2019","journal-title":"Invest New Drugs"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100315_bib27","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1111\/jdv.15818","article-title":"Phototoxic reaction to brigatinib \u2013 a new photosensitizing drug","volume":"33","author":"Morgado","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"23","key":"10.1016\/j.esmoop.2021.100315_bib28","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10072","key":"10.1016\/j.esmoop.2021.100315_bib29","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100315_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2021.100315_bib31","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I","article-title":"Patient noncompliance with self-administered chemotherapy","volume":"65","author":"Lebovits","year":"1990","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib33","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100315_bib34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.3389\/fphar.2018.01567","article-title":"A\u00a0novel approach to better characterize medication adherence in oral anticancer treatments","volume":"9","author":"Schneider","year":"2019","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100315_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","author":"Hershman","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100315_bib36","unstructured":"Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). 2018. Available at https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed April 11, 2021."},{"issue":"4","key":"10.1016\/j.esmoop.2021.100315_bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.esmoop.2021.100315_bib38","doi-asserted-by":"crossref","unstructured":"Medical Dictionary for Regulatory Activities. Welcome to MedDRA. Medical Dictionary for Regulatory Activities. 2018. Available at https:\/\/www.meddra.org\/. Accessed April 11,\u00a02021.","DOI":"10.5958\/0974-360X.2018.00866.1"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100315_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A\u00a0comparison of measures of disproportionality for signal detection is spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100315_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Safety"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100315_bib42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A\u00a0Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100315_bib44","unstructured":"van Rossum G. Python Release Python 3.6.0 | Python.org. 2016. Available at https:\/\/www.python.org\/downloads\/release\/python-360\/. Accessed April 11,\u00a02021."},{"key":"10.1016\/j.esmoop.2021.100315_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.11.004","article-title":"Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review","volume":"134","author":"Kassem","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100315_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2407-13-207","article-title":"Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma","volume":"13","author":"Gennatas","year":"2013","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100315_bib49","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jtho.2018.10.154","article-title":"Pulmonary arterial hypertension in ALK receptor tyrosine kinase-positive lung cancer patient: adverse event or disease spread?","volume":"14","author":"Tabb\u00f2","year":"2019","journal-title":"J\u00a0Thoracic Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100315_bib50","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21693\/1933-088X-17.2.69","article-title":"Tyrosine kinase inhibitor-induced pulmonary arterial hypertension","volume":"17","author":"Preda","year":"2018","journal-title":"Adv Pulm Hypertens"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100315_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100315_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin Drug Investig"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:11Z","timestamp":1761855971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2059702921002775"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100315","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100315"}}